Javascript must be enabled for the correct page display
Skip to Content
In the News

Bora Biologics Welcomes Dr. Roger Lias to its Executive Team

“Customers need more than manufacturing capacity. They need a partner who understands their program, communicates openly, and anticipates what comes next. I look forward to working with the Bora Biologics team to help customers build practical manufacturing pathways from development through commercial supply.” – Roger Lias, PhD

Bora Biologics is pleased to welcome Dr. Roger Lias to its executive team. Dr. Lias will lead the company’s global commercial activities, helping customers connect their development and manufacturing needs with Bora Biologics’ mammalian and microbial capabilities.

Dr. Lias brings extensive executive leadership and commercial experience across the global biologics CDMO industry. His background includes commercial roles at Celltech/Lonza and Diosynth, founding management roles at KBI Biopharma, Cytovance Biologics, and Eden Biodesign, and CEO positions at Avid Bioservices and Stelis Biopharma.

More recently, he has supported CDMOs through start-up, growth, and turnaround initiatives and was part of the team involved in the sale of Vibalogics to Recipharm. His experience spans North America, Europe, and Asia-Pacific.

At Bora Biologics, Dr. Lias will work with customers ranging from emerging biotechnology companies to multinational biopharma organizations. His focus will be on understanding each program’s requirements and aligning the right technical expertise, manufacturing capabilities, and commercial approach to support its next milestone.

Bora Biologics supports the development and manufacturing of antibodies and other recombinant proteins derived from mammalian and microbial expression systems. With facilities in Zhubei, Taiwan; Rockville, Maryland; and San Diego, California, our services span cell line development, process development, technology transfer, and GMP manufacturing for clinical and commercial supply.

Dr. Lias’ appointment reinforces Bora Biologics’ commitment to helping customers reduce execution risk, strengthen manufacturing readiness, and move forward with confidence.

 

Bora Biologics

the logical choice

Join the ranks of biopharma pioneers who trust us.
Explore how we minimize risks and accelerate your success.

Partner with us

Client-Centric

100% commitment to supporting your success

We have been the client, bringing multiple biologics from IND to BLA. Your needs and goals are at the forefront of our approach. By involving you in every step of the process, we ensure transparency and alignment, reducing the likelihood of misunderstandings and ensuring the outcome meets your expectations.

Experience

15+ years developing & manufacturing biologics

We have honed our ability to navigate complexities. Our track record from concept to commercialization means we can apply best practices and lessons learned, ensuring smoother project execution.

Expertise

Over 200 seasoned scientists & regulatory professionals

Our team exudes deep knowledge and specialized skills. This expertise allows us to foresee potential challenges and implement proactive solutions, reducing the likelihood of setbacks.

Commercial-Ready

2 US FDA registered GMP manufacturing facilities

We focus on delivering solutions that are ready for market. With clinical to commercial scale facilities consistently meeting compliance standards, we ensure your project is primed for success, minimizing the risk of costly revisions or delays.

Allied

access to global CDMO resources

Our partnership with Bora Pharmaceuticals provides additional resources and insights. This network enables us to leverage shared knowledge and expertise, further mitigating risks and accelerating the overall success of your project.